Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Moderna will also assume further development, manufacturing, and commercialisation responsibilities on exercising a target option.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Pharmaceutical Technology

AUGUST 14, 2023

HebeCell has forged a strategic collaboration with Logomix for researching and developing gene-edited natural killer cells (NK cells).

Gene Editing 246

Gene Editing Development Gene Research 246

Bio Pharma Dive

JANUARY 6, 2024

The Emeryville, California- based gene therapy developer has several preclinical programs in development with Moderna, Ionis and Affini-T.

Gene Editing 208

Gene Editing Gene Gene Therapy Development 208

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 257

Gene Editing Gene In-Vivo RNA 257

pharmaphorum

JANUARY 29, 2021

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. That would just slow the whole field down.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

STAT News

FEBRUARY 22, 2023

Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions.

Gene Editing 126

Gene Editing Gene Genetic Disease Gene Therapy 126

Bio Pharma Dive

FEBRUARY 28, 2024

The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes that can be used to make genetic medicines.

Gene Editing 169

Gene Editing Gene Genetics Medicine 169

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 286

Gene Editing Insulin Gene Licensing 286

Bio Pharma Dive

NOVEMBER 8, 2023

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

Gene Editing 325

Gene Editing Gene Development 325

Drug Discovery World

DECEMBER 6, 2023

Gene editing company Eligo Bioscience has announced a successful $30 million Series B funding round, led by Sanofi Ventures. “We The funding is earmarked for accelerating the development of Eligo’s flagship programme, EB005, which targets moderate to severe acne vulgaris.

Gene Editing 52

Gene Editing Gene In-Vivo Genetics 52

STAT News

NOVEMBER 14, 2022

Ionis will pay the Bay Area gene-editing startup $80 million upfront as the companies work together to develop up to four gene-editing therapies, with the option to add four more targets.   On Monday, the company announced a partnership with Metagenomi to kickstart these efforts.

Gene Editing 98

Gene Editing RNA Gene Drugs 98

Bio Pharma Dive

NOVEMBER 20, 2020

Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy.

Gene Editing 258

Gene Editing Gene Genetics Development 258

Bio Pharma Dive

SEPTEMBER 9, 2021

Formed as a diagnostics developer, Mammoth Biosciences, which Doudna started with two of her former students at the University of California, has accelerated plans to make gene editing medicines as well.

Gene Editing 271

Gene Editing Development Gene Medicine 271

BioPharma Reporter

JANUARY 10, 2022

have announced a strategic collaboration and option agreement for the use of Mammothâs CRISPR systems to develop in vivo gene-editing therapies. Bayer AG and Mammoth Biosciences, Inc.,

Gene Editing 96

Gene Editing Gene In-Vivo Development 96

Bio Pharma Dive

JUNE 15, 2021

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.

Gene Editing 281

Gene Editing Gene Genetics Development 281

Scienmag

MAY 2, 2022

WINSTON-SALEM, NC – May 2, 2022 — Wake Forest Institute for Regenerative Medicine (WFIRM) scientists working on CRISPR/Cas9-mediated gene editing technology have developed a method to increase efficiency of editing while minimizing DNA deletion sizes, a key step toward developing gene editing therapies to treat genetic diseases.

Gene Editing 58

Gene Editing DNA Gene Development 58

Drug Discovery World

NOVEMBER 30, 2023

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. The post CRISPR gene editing ‘cancer shredding’ technique destroys brain tumours appeared first on Drug Discovery World (DDW).

Gene Editing 59

Gene Editing Gene Genetics DNA 59

Scienmag

JUNE 28, 2022

AMES, IA – Through CRISPR and other gene-editing technologies, researchers and developers are poised to bring dozens – if not hundreds – of new products to grocery stores: mushrooms with longer shelf lives, drought-resistant corn and bananas impervious to a fungus threatening the global supply.

Gene Editing 88

Gene Editing Gene Production Development 88

Bio Pharma Dive

OCTOBER 18, 2023

Developed with Regeneron, Intellia’s treatment is designed to inactivate a gene to treat an inherited disease called transthyretin amyloidosis.

Gene Editing 161

Gene Editing Gene Development 161

Bio Pharma Dive

AUGUST 7, 2020

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership.

Gene Editing 334

Gene Editing Gene Trials Development 334

BioPharma Reporter

NOVEMBER 16, 2021

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Gene Editing 111

Gene Editing Gene Clinical Trials Clinical Trials 111

Bio Pharma Dive

NOVEMBER 14, 2022

The RNA drug developer is paying the richly-funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines.

Gene Editing 161

Gene Editing RNA DNA Gene 161

Bio Pharma Dive

NOVEMBER 17, 2022

While the biotech will not develop the gene editing therapy further on its own, CEO Gilmore O’Neill claimed the data are still a meaningful demonstration of what CRISPR can accomplish.

Gene Editing 306

Gene Editing Medicine Gene Development 306

Drug Discovery World

OCTOBER 11, 2022

A team of researchers at Northwestern University in the US has devised a new platform for gene editing that could inform the future application of CRISPR-based therapeutics. They created a system to deliver the cargo required for generating the gene editing machine known as CRISPR-Cas9. High gene editing efficiency.

Gene Editing 52

Gene Editing Gene DNA Protein 52

pharmaphorum

SEPTEMBER 28, 2022

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this year. The time places exa-cel in pole position to become the first drug developed based on CRISPR/Cas9 gene-editing technology to reach the market.

Gene Editing 59

Gene Editing Gene In-Vivo Clinical Trials 59

Bio Pharma Dive

FEBRUARY 23, 2021

Guide Therapeutics, the company Beam acquired, is working on ways to more efficiently deliver gene editing therapies into the body.

Gene Editing 283

Gene Editing Gene Gene Therapy Development 283

Bio Pharma Dive

JANUARY 19, 2023

Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology.

Gene Editing 258

Gene Editing Licensing Licensing Gene 258

Bio Pharma Dive

JUNE 22, 2022

The pharma will pay $75 million to access Precision’s gene editing technology, adding another program to the lengthening list of drug development efforts targeting the inherited blood condition.

Gene Editing 300

Gene Editing Gene Development Drugs 300

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The team then engineered the phages through gene editing to improve their targeting ability.

Development 246

Development Bacteria Research Gene Editing 246

pharmaphorum

JUNE 12, 2022

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease. billion product if it gets approved for both indications.

Gene Editing 59

Gene Editing Gene Gene Therapy Drugs 59

BioTech 365

SEPTEMBER 29, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: UK permits development of gene-edited crops in climate fight.Britain’s government plans to allow researchers to use gene-editing techniques to develop crops that can increase yields, reduce the … Continue reading → (..)

Gene Editing 40

Gene Editing Gene Development Research 40

BioPharma Reporter

FEBRUARY 23, 2023

The messenger RNA (mRNA) specialist Moderna has teamed up with ElevateBio-owned Life Edit Therapeutics to develop gene editing therapies that are delivered into patients in vivo.

Gene Editing 52

Gene Editing Genetic Disease Gene In-Vivo 52

Bio Pharma Dive

AUGUST 24, 2021

A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others.

Gene Editing 242

Gene Editing Gene Development 242

pharmaphorum

OCTOBER 13, 2022

Gene therapies and research into them have grown immensely in recent years, offering more novel tools in regenerative medicine to fight disease, including rare diseases and genetic disorders. billion deal with Precision Biosciences to support its development of one-time treatments for beta-thalassemia and sickle cell.

Gene Editing 52

Gene Editing Gene Gene Therapy Genetics 52

Medical Xpress

MAY 11, 2023

Genomic studies of cancer patients have revealed thousands of mutations linked to tumor development. However, for the vast majority of those mutations, researchers are unsure of how they contribute to cancer because there's no easy way to study them in animal models.

Gene Editing 130

Gene Editing Gene Genome Genomics 130

Pharmaceutical Technology

JUNE 8, 2023

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130

Genome Genomics Medicine Development 130

Bio Pharma Dive

OCTOBER 13, 2021

The gene editing company will take a 10% stake in SparingVision, a young biotech that will use Intellia's CRISPR technology to develop treatments for up to three ocular targets.

Gene Editing 286

Gene Editing Gene Development 286